DISCLAIMER: This is a quantitative framework for educational purposes only. It is not financial advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
| Horizon | Signal | Composite Score | Confidence | Key Driver |
|---|
| Short-term (1-3 mo) |
BUY (accumulate on weakness) |
58 |
66% |
Pullback in a higher-timeframe uptrend; near-term momentum soft — let weakness come to you |
| Medium-term (6-12 mo) |
BUY |
62 |
70% |
Cheap on normalized earnings (~12-13x) + ~14% to consensus + defensive macro tailwind |
| Long-term (3-5 yr) |
BUY |
64 |
72% |
High-quality cash machine at a discount; Keytruda 2028 cliff is the central watch-item |
No amplification fired — driver Neutral (54, <65), so no horizon reaches STRONG BUY despite a macro Tailwind. ·
Next update: 2026-06-30 — default +14d (next earnings ~Jul 28 is beyond the 14-day window).
1
Five-Pillar Scorecard
Five independent scores — Business Quality, Valuation Attractiveness, Entry/Exit Timing, Underlying Drivers, and Economic Alignment — each 0–100 with confidence. The per-horizon base BUY/HOLD/SELL comes from the three fundamental pillars (Quality / Valuation / Timing) via the Decision Matrix; the two context pillars (Underlying Drivers, Economic Alignment) then amplify a BUY to STRONG BUY or a SELL to STRONG SELL only when both corroborate. Here Quality is High (67) and Valuation is Attractive (65), so the matrix returns BUY at every Timing band — the soft Timing (51) lives in the score and the entry rules, not in a suppressed signal.
Business Quality
67
Fortress economics; single-product concentration the caveat
Confidence: 72%
Valuation Attractiveness
65
~12-13x normalized earnings; ~14% to consensus
Confidence: 78%
Entry/Exit Timing
51
Higher-TF uptrend, but daily/hourly rolling over
Confidence: 70%
Underlying Drivers
54
Pipeline-vs-Keytruda-cliff: net Neutral
Confidence: 62% · no amplification (need ≥65)
Economic Alignment
62
Trend-Following · Tailwind
Confidence: 65% · Macro report 2026-06-13
2
Hard Gates & Do-Not-Buy Status
Binary safety checks — financial distress, earnings-event risk, valuation ceiling, accounting/dilution, regulatory binary, and the sector-specific patent-cliff concentration check. A TRIGGERED gate caps or blocks the signal regardless of the composite; CAUTION gates are notes for position sizing, not blocks. No Do-Not-Buy trigger fired here, but two CAUTIONS plus the cliff-concentration flag are live — hence the overall ⚠ caution state.
✅Financial Distress — CLEAR
Net debt ~$44B / ~1.7x normalized EBITDA; interest coverage 17.4x; current ratio 1.30.
✅Earnings Event Risk — CLEAR
Next print ~Jul 28 2026 (Q2, est.) — beyond the 14-day window. No blackout.
✅Valuation Ceiling — CLEAR
$115.17 sits below the $150 high target and well below extreme multiples on normalized earnings.
⚠️Accounting / Dilution — CAUTION
Large GAAP/non-GAAP gap from the ~$9B Q1 Cidara IPR&D charge (+ a proposed Terns charge). One-time and well-disclosed; share count is falling (2,541M→2,472M) via buybacks. Optics only.
⚠️Regulatory / Drug Pricing — CAUTION
IRA Medicare price-negotiation and pricing policy is a persistent overhang for large-cap pharma. No imminent single binary FDA event.
⚠️Concentration / Patent Cliff — CAUTION
Keytruda/Qlex was $8.0B in Q1 (~49% of total revenue, ~53% of pharma). US loss-of-exclusivity / biosimilars from ~2028. The dominant risk to the thesis.
✅Severe Driver Collapse — CLEAR
Driver score 54 (Neutral), well above the ≤15 collapse threshold. Keytruda still +12% YoY.
✅Do-Not-Buy Triggers — NONE
No leverage+rates spiral, no valuation extreme, no sustained negative revisions, no insider-selling spike.
3
Pillar Detail: Business Quality
Deep dive into the Quality score for a mature pharma: revenue durability, margins, cash generation, balance sheet, the R&D-efficiency + patent-cliff industry benchmark, competitive moat, and ROIC/capital allocation. Read this to understand why Quality scored 67 — an excellent business whose one demerit (single-product concentration) is structural, not operational.
Business Quality — Pillar Score
A genuine high-quality compounder — 76% gross margin, ~28% operating margin, 17x interest coverage, falling share count and top-quartile ROIC — held back from a higher score only by ~49% revenue concentration in Keytruda and the looming 2028 cliff.
67
Confidence 72% · High (≥65)
Lifecycle & Sector Classification
Stage 4 — Mature (low-single-digit revenue growth, highly profitable, stable cash flow). Sector profile: Healthcare / Pharma (Mature). Metrics emphasised: revenue durability & diversification, R&D efficiency, ROIC, FCF yield, forward P/E vs pharma peers, dividend sustainability. Dynamic macro weight: Low (10%) — pharma demand is largely acyclical.
| Sub-Signal | Value (MRK) | Pharma context | Score | Rationale |
|---|
| Revenue trajectory | TTM ~$65.6B; FY25 ~flat-to-low single digit | Big-pharma median ~3-5% | 55 | Mature top line; Keytruda +12% and Winrevair +88% offset Gardasil (China) softness. |
| Profitability vs peers | Gross 75.9% · Operating ~27.6% | Top-tier pharma margins | 82 | Margins among the best in large-cap pharma; pricing power on innovative drugs. |
| Cash generation | FCF/share $5.71 TTM (depressed by $9B Cidara cash outlay); normalized ~$6-7 | Strong cash converter | 75 | Normalized FCF ~$15-18B; TTM understated by the one-time Cidara payment. |
| Balance-sheet health | Net debt ~$44B · ~1.7x EBITDA · coverage 17.4x | <2.0x healthy | 78 | Investment-grade fortress; ample capacity for BD and dividends. |
| Revenue durability / diversification | Keytruda ~49% of revenue; US LOE ~2028 | >30% at-risk = red flag | 38 | The framework's red-flag zone — single-product concentration is the core durability risk. |
INDUSTRY BENCHMARK: R&D Efficiency + Patent-Cliff Exposure
R&D productivity: strong — multiple recent launches (Winrevair/sotatercept in PAH, Welireg, Enflonsia in RSV, Capvaxive, subcutaneous Keytruda Qlex) and a deep oncology/cardio pipeline. Patent-cliff exposure: red-flag — Keytruda ~49% of revenue with US biosimilar entry from ~2028.
Rating: MIXED — productive pipeline running into a large, concentrated cliff. Benchmark Score: 52/100.
Context: the pipeline is credible enough that consensus models revenue growth through 2028 ($66.7B '26E → $74.9B '28E), but the franchise math means execution has no margin for error.
Competitive Moat
Pricing Power
66
Innovative-drug pricing, but IRA caps it
Network Effects
50
N/A — neutral 50
Switching Costs
58
Standard-of-care inertia in oncology
Cost Advantage
60
Scale in manufacturing & trials
Intangible Assets
85
Patents, brands, regulatory data moat
Moat average ≈ 64. The moat is real but time-bound: patent protection is the dominant intangible, and it is precisely the asset that erodes at the 2028 cliff. The durability question is whether the next wave of patents (Winrevair, Qlex, oncology pipeline) rebuilds the moat as Keytruda's decays.
ROIC & Capital Allocation
FMP health rating B (3/5) with ROE 5/5 and ROA 5/5 — returns on capital are top-quartile for the sector (the B is dragged down by leverage- and multiple-based sub-scores that misread the distorted trailing P/E). Capital allocation is disciplined: a growing dividend ($0.81→$0.85/qtr, ~38% payout on normalized EPS), buybacks shrinking the count, and aggressive business development (Cidara, Verona/ohtuvayre via Verona, Terns) explicitly aimed at the cliff. Management skin-in-the-game is moderate (institutional ownership; modest insider stakes typical of mega-cap pharma). ROIC/capital sub-score ≈ 70.
4
Pillar Detail: Valuation Attractiveness
Deep dive into Valuation — and this is where the report earns its keep. MRK's reported multiples are badly distorted by a ~$9B one-time Cidara IPR&D charge that crushed trailing and 2026 EPS. Below we show the reported figures, the normalization bridge, and the true picture: a high-quality pharma at ~12-13x normalized earnings with ~14% upside to consensus. Includes FCF yield, reverse-DCF implied growth, embedded optionality, the analyst target range, grades distribution, and the FMP cross-reference.
Valuation Attractiveness — Pillar Score
Attractive on a normalized basis: cheap forward multiple, mid-single-digit normalized FCF yield, and a reverse-DCF that prices in almost no growth — the cliff is the reason it's cheap, and the discount looks more than fair for a business consensus still models growing.
65
Confidence 78% · Attractive (≥65)
⚠ Normalization bridge — do NOT value MRK on reported 2026 EPS
| Metric | Reported (distorted) | Why distorted | Normalized basis |
|---|
| EPS (FY2026) | $5.04–5.16 guide
($5.14 cons.) | Includes ~$9B Cidara IPR&D charge (~$3.5/sh after-tax) + proposed Terns charge — Merck books one-time BD in non-GAAP EPS | ~$8.7–9.0 ex-charge
(FY25 ~$8.93; FY27 cons. $9.64) |
| P/E | Trailing 31.9x · 22.4x on '26 guide | Both divide by charge-depressed EPS | ~12.8x on ~$9.0
~11.9x on FY27 $9.64 |
| FCF yield | ~4.3% (FCF/EV TTM) | TTM FCF absorbed the ~$9B Cidara cash outlay | ~6% normalized |
| Dividend payout | 92% (TTM EPS) | Depressed EPS denominator | ~38% on normalized EPS |
| Reference / Multiple | Value | Benchmark | Read |
|---|
| Forward P/E (normalized) | ~12.8x ('26 norm) · 11.9x ('27) | Large-pharma median ~14-16x | Below peers — Attractive |
| Own historical decile | ~12-13x vs typical 13-16x range | Lower third of 5-yr band | Decile ~3 — Attractive |
| FCF yield (normalized) | ~6% | 5-8% attractive | Attractive |
| P/B · P/S | 6.2x · 4.3x | Reflects asset-light, high-margin model | Fair |
| EV/EBITDA (normalized) | ~13x on ~$25B EBITDA | Pharma ~11-13x | Fair-to-attractive |
| Dividend yield | ~2.95% ($3.40 annualized) | Growing, ~38% normalized payout | Well-covered income |
Reverse DCF — what is the market pricing in?
At $115.17 with EV ~$328B and normalized FCF ~$15-16B (≈10% WACC), the market is implying roughly 2-3% long-run FCF growth — essentially a slow fade. Consensus, by contrast, models revenue from $66.7B (2026E) to $74.9B (2028E), i.e. mid-single-digit growth straight through the cliff window. Implied growth < consensus growth → the market is pricing pessimism the pipeline may not deliver. That gap is the bull case; it is also a warning that if the pipeline disappoints, the "cheap" multiple has room to stay cheap.
Embedded Optionality / Free Upside
- Subcutaneous Keytruda (Qlex) — a partial defense against the IV-biosimilar cliff via formulation switch and fresh IP; the market is only beginning to credit the conversion.
- Winrevair (sotatercept) — $525M in Q1, +88% YoY; a credible multi-billion franchise the slow-pharma multiple under-prices.
- BD pipeline already paid for — Cidara (anti-infective) and the proposed Terns deal were expensed up front (the very charge depressing EPS), so their pipeline value is owned for ~free in today's price.
- Animal Health — a steady, non-correlated segment buried inside the pharma multiple; sum-of-the-parts gap.
Net: the in-production core (ex-Keytruda-cliff-risk) justifies most of the $115 price; the cliff-defense pipeline + Winrevair ramp + Animal Health are the call options. Optionality is treated as a small +5 tilt here, not a re-rating — it raises conviction the downside is cushioned, not that the core is mispriced on hope.
Analyst Consensus & Cross-References
| Source | Reading | Signal |
|---|
| Price-target consensus | Consensus $131.58 · Median $135 · High $150 · Low $100 (price $115.17) | +14% to consensus, +17% to median — Attractive (≈78) |
| Coverage depth / recency | 21 targets last year; wide $100–$150 spread | Deep coverage; wide spread = genuine cliff disagreement (−10% conf.) |
| Grades consensus | 25 Buy · 11 Hold · 1 Sell · 0 Strong (67.6% bullish) | Buy consensus with ~30% holds (≈68) |
| Recent grade actions | All "maintain" (Wells Fargo OW, UBS Buy, JPM OW, RBC OP) — no up/down in 90 days | Stable, no momentum either way |
| FMP ratings snapshot | B (3/5): DCF 4, ROE 5, ROA 5; D/E 1, P/E 1, P/B 1 | Returns excellent; leverage/multiple sub-scores misread the distorted P/E |
5
Pillar Detail: Underlying Drivers
The dominant external force MRK is tethered to is pipeline-vs-patent-cliff durability — specifically whether the launch pipeline can backfill the Keytruda franchise as US exclusivity lapses from ~2028. This is a context pillar: it does not change the fundamental scores, but a tailwind ≥65 could lift a BUY to STRONG BUY and a headwind ≤35 could push a SELL to STRONG SELL. It also names the thesis-invalidation floor.
| Horizon | Weight | Read | Sub-score |
|---|
| Historical (12-24mo) | 25% | Strong franchise execution; Winrevair launch; subcutaneous Keytruda approved & ramping | 70 |
| Current state | 50% | Keytruda still growing (+12%); no cliff impact yet; multiple new drugs launching | 62 |
| Forward outlook | 25% | Headwind — US LOE / biosimilars from ~2028; IRA pricing pressure; backfill credible but unproven at franchise scale | 40 |
Composite = 0.25·70 + 0.50·62 + 0.25·40 = 54 (Neutral, 50-64). The patent-cliff sub-signal is scored as a clear forward headwind (40); it is offset — but only to Neutral, not tailwind — by current franchise momentum and a credible launch pipeline. Because 54 < 65, the driver is not eligible to amplify any horizon to STRONG BUY, even though the macro pressure is a Tailwind (§6). The base BUY signals stand unchanged.
Thesis-invalidation floor: the case breaks if (a) Keytruda biosimilar erosion arrives faster/deeper than modelled with the pipeline failing to backfill (revenue declines into 2028-29 rather than growing), and/or (b) a major pipeline readout (oncology/cardio) or the Winrevair/Qlex ramp disappoints. Either would turn this driver into a genuine Headwind and re-open downside toward the bear case.
Driver confidence 62% — base 70, −8 because the cliff's exact timing/magnitude is contested and the backfill is forward-looking.
6
Pillar Detail: Economic Alignment
How the current economic climate sits relative to MRK, read from the latest Macro-Economic report. It classifies the macro pressure as Tailwind / Neutral / Headwind and frames a long entry as Trend-Following or Contrarian with a 0–100 conviction. The pressure is the second amplification input — but it only fires a STRONG signal alongside a ≥65 driver, which is not the case here.
The macro report scores Health Care (XLV) Short: Outperform · Medium: Outperform · Long: Neutral. In a stagflation regime, defensive, cash-generative, demand-inelastic health care attracts a relative bid — exactly the profile of large-cap pharma. Anchoring on the Medium horizon, the economic pressure is a Tailwind, so a long here is Trend-Following (riding the defensive rotation), with conviction 62 (moderate — the tailwind is real but the Long signal is only Neutral, and pharma's macro sensitivity is Low regardless).
Amplification check: pressure = Tailwind ✓, but the Underlying Driver is 54 (<65) ✗. Both conditions must hold, so no horizon is amplified to STRONG BUY — the Tailwind reinforces conviction in the BUY direction but does not intensify the label. Confidence 65% (sector-map rather than a name-specific watchlist signal; macro report 3 days old — fresh).
7
Pillar Detail: Entry/Exit Timing
Deep dive into Timing: the risk-reward framework anchored to the stop, relative strength, the ATR/stop-distance position-risk signal, the low-weight macro overlay, news/grade-derived sentiment, and the catalyst calendar. Read this to understand when to act — MRK is a good business at a fair-to-cheap price caught mid-pullback, so timing is the weak leg even as the signal stays BUY.
Entry/Exit Timing — Pillar Score
Constructive but unconfirmed: monthly and weekly trends are up and price holds well above the rising 200-day, but the daily has weakened and the hourly has rolled over after a pullback from ~$125. A textbook "dip in a higher-timeframe uptrend" that hasn't yet turned back up — hence accumulate-on-weakness rather than chase.
51
Confidence 70% · Neutral
| Timing component | Reading | Score |
|---|
| MTF trend (weighted) | Monthly & weekly uptrend; daily weakening; hourly downtrend; 15-min recovering | 57 |
| Risk-reward / position-risk | $115.17 vs support $110.9 / $107.9 / 200-day $104.9; resistance $122-125. ATR(daily) $3.23 — stop ~$104.5 is ~3.3 ATR (wider than ideal) | 48 |
| Relative strength | +50% off the $76.66 52-wk low; pharma/defensives leading in 2026 — strong RS, now mid-pullback at 79% of the 52-wk range | 68 |
| Macro overlay (10% weight) | VIX 16.2 (risk-on-ish), Fed on hold ~3.63%, XLV in favour | 62 |
| Sentiment (grades + news) | All grade actions "maintain"; light, neutral news flow | 50 |
| Catalyst layer | No earnings within 14 days; calm calendar (clustering ~70) | 70 |
Weighted (MTF 30% · risk-reward 20% · macro 10% · sentiment 20% · catalyst 20%) ≈ 51. Translation: the trend structure favours longs, but momentum is soft right now — the disciplined move is to accumulate into weakness toward the $108-111 support shelf rather than buy the current bounce.
8
Economic Event Risk
Next ~2 weeks of high-impact US macro releases plus recent surprises. Pharma is a Low macro-sensitivity sector, so there is no WAIT-FOR-EVENT override here — but the FOMC tomorrow and the broad-market tape still matter for entry timing.
| Date | Event | Impact | Forecast / Prev | Relevant to MRK? |
|---|
| Jun 17 | FOMC rate decision + projections + presser | High | Hold 3.75% (prev 3.75%) | Low-direct — sets risk appetite / discount rate, not pharma demand |
| Jun 17 | Retail Sales MoM (May) | High | +0.5% / +0.5% | Low — consumer, not pharma |
| Jun 18 | Philly Fed (Jun) | Low/Med | — | Low |
| ~Jul 28 (est.) | MRK Q2 2026 earnings | High (stock-specific) | Watch Keytruda, Winrevair, FY guide | ✅ The real catalyst — beyond the 14-day window, so it sets the next update, not this one |
Recent tape: June data softened (Empire State 5.7 vs 14 f'cast; Industrial Production +0.1% MoM; Housing Starts −15.4%) and Atlanta Fed GDPNow eased to 2.8% — consistent with the stagflation/soft-landing read that favours defensives like pharma. None of this is directly MRK-relevant; the only event that moves this stock is its own Q2 print (~Jul 28, estimated — get_earnings_calendar returned no dated row, so treat the date as provisional).
9
Multi-Timeframe Technical Analysis
Trend, RSI, MACD and breakout status across monthly → 15-minute, plus the confluence verdict. The pattern to spot here is "higher-timeframe uptrend + lower-timeframe pullback" — constructive for buying weakness, but it asks for patience until the daily turns back up.
| Timeframe | Trend | RSI | MACD hist | Key S / R | Breakout | Vol |
|---|
| Monthly | Uptrend ↑ | 57.4 | +3.03 (rising) | S 94.5 / R 125.1 | Resistance breakout | 0.5x |
| Weekly | Uptrend ↑ | 52.9 | −0.95 (fading) | S 105.8 / R 123.5 | Resistance breakout | 0.5x |
| Daily | Weakening → | 45.0 | −0.17 | S 110.9 / R 122.2 | (below 20/50-day, above 200-day $104.9) | 1.4x |
| Hourly | Strong downtrend ↓ | 43.1 | +0.19 (basing?) | S 113.6 / R 118.9 | Support breakdown | — |
| 15-min | Recovering → | 52.3 | ~flat | S 114.5 / R 115.9 | Resistance breakout | — |
| Confluence | Mixed/transitioning — MTF trend score ≈ 57. Higher-TF bullish, lower-TF pullback. |
Monthly and weekly remain solidly up and price sits ~10% above the rising 200-day ($104.9), so the primary trend is intact. The daily has slipped below its 20- and 50-day after fading from ~$125, and the hourly has broken short-term support — classic counter-trend pullback. The constructive read: this is a dip within an uptrend, with a strong support cluster at $108-111 (daily swing lows) reinforced by the 200-day below. A daily close back above the 20-day (~$117.8) on rising MACD would confirm the resumption.
10
Price Chart (6-Month Daily)
Six months of daily closes with the 50-day SMA and key support/resistance overlaid. Visual companion to §9: the December–February run from ~$98 to $125, the spring consolidation, and the current pullback toward the $108-111 support shelf.
11
Scenario Summary
Bull / Base / Bear 12-month paths with triggers and probability weights. The base case is a gradual re-rating toward consensus as cliff fear moderates; the tails hinge almost entirely on how the Keytruda-cliff-vs-pipeline question resolves.
Bull — $148 (+29%) · 25%
Winrevair, Welireg, Enflonsia and subcutaneous Keytruda (Qlex) ramp faster than modelled; Qlex conversion blunts the biosimilar cliff; a pipeline readout de-risks 2028. Multiple re-rates to ~16x normalized EPS. Trigger: Q2/Q3 beats + raised guide + positive late-stage data.
Base — $131 (+14%) · 50%
Normalized EPS grinds toward ~$9.5 by 2027; cliff fear moderates as backfill proves out; multiple drifts to ~14x and the dividend keeps growing. Converges on the $131.58 consensus. Trigger: in-line execution, no negative surprises.
Bear — $98 (−15%) · 25%
Keytruda erosion fears intensify, a pipeline readout disappoints, or IRA/pricing pressure bites; the multiple stays ~11x on flat-to-down normalized EPS. Retests late-2025 levels. Trigger: guide cut, pipeline miss, or biosimilar timeline pulled forward.
12
Entry / Exit Rules
Mechanical conditions to enter and exit. Entry needs multiple independent checks; exits are governed by a hard stop, thesis invalidation, and scaled profit-takes. At $115.17, 1 of 3 entry criteria are met and 0 of 3 exit criteria are live.
Entry Rules — 1 / 3 met
Rule 1 (Fundamental) — ✅ MET: Price < fair value $131 ($115.17 ✓) AND no earnings within 7 days (✓) AND driver ≥ 50 (54 ✓). The valuation/fundamental gate is open.
Rule 2 (Technical) — ✗ not met: daily close back above the 20-day SMA (~$117.8) on volume >1.5× 20-day average, with RSI 35-65 and MACD histogram positive ≥2 days. Forecast: ~1-3 weeks if the dip holds the $108-111 shelf and turns up.
Rule 3 (Value-add) — ✗ not met: pullback into the $108-111 support shelf (or within 3% of the 200-day $104.9) for a larger tranche. Forecast: needs a further ~4-6% dip; catalyst-dependent.
Exit Rules — 0 / 3 live
Rule 1 (Stop-loss): daily close below $104.50 (under the 200-day and the support cluster) for 2 consecutive days. Not triggered — price is 9% above.
Rule 2 (Thesis invalidation): FY guide cut AND a Keytruda/pipeline event that confirms the backfill is failing (revenue set to decline into 2028-29). Not triggered.
Rule 3 (Profit-take): price ≥ $135 (median target) AND RSI > 70 AND no quality improvement to justify the new multiple → trim. Not triggered.
Imagine you act at the current price $115.17 · as of Jun 16, 2026
What if you bought now?
You'd be risking ~$10.67 / −9.3% to the hard stop to gain ~$15.83 / +13.7% to the base target.
- Risking: downside to stop $104.50 (−9.3%); bear case $98 (−14.9%); plus — Technical entry NOT yet met (buying into a soft daily/hourly tape, above the $108-111 add zone) and the structural Keytruda-cliff overhang.
- Gaining: base $131 (+13.7%) · bull $148 (+28.5%); plus a growing ~2.95% dividend and the cliff-defense optionality (Qlex, Winrevair) you own for ~free while you wait.
- Net: risk-reward ≈ 1.5:1 to base, ~3:1 to bull. Acting now is reasonable for a starter tranche; waiting for a daily turn-up or the $108-111 shelf materially improves the entry.
What if you sold now?
You'd be giving up ~+13.7% base-case upside to protect against a ~−15% bear drawdown.
- Giving up: upside to $131 (+13.7%) and the bull path to $148; the growing dividend and cliff-defense optionality; selling ~12% below the $131.58 consensus / ~$131 fair value.
- Protecting: capital if the bear case ($98) plays out. But no exit rule is triggered right now — not the stop, not thesis invalidation, not the profit-take.
- Net: with nothing mechanically triggered and price below fair value, this reads as a hold/accumulate zone, not a sell.
13
Position Sizing Context
Illustrative portfolio math, not advice. No risk budget or portfolio role was provided for this batch run, so position size is not computed — what follows is volatility context to frame what owning MRK feels like.
Position sizing not computed — specify your portfolio allocation and role for sizing guidance. Volatility context: daily ATR $3.23 ≈ 2.8% of price (low for a single stock); beta 0.22 — MRK moves far less than the market, a genuine defensive ballast. The hard stop at $104.50 implies ~9.3% risk-per-share from here; a pullback-based, staggered entry (a starter now, adds at $108-111 and near the 200-day $104.9) keeps average risk tight. Catalyst density is calm (no events within 14 days), so no event-driven size reduction is warranted ahead of the ~Jul 28 print.
14
Calibration Snapshot
Machine-readable snapshot of every score, level, and override, saved alongside the HTML as calibration-MRK-20260616-1703.json for the next run's deltas and the watchlist monitor. This is MRK's first Donatien report — no prior calibration, so no "Changes Since Last Report".
{
"ticker": "MRK", "exchange_ticker": "NYSE:MRK", "isin": "US58933Y1055",
"date": "2026-06-16", "version": "v6", "prior_report": null,
"analysis_status": "on-going", "finder_ticker": "MRK", "finder_exchange": "🇺🇸 NYSE",
"section": "Defensive Health Care",
"sector": "Healthcare / Pharma (Mature)", "lifecycle_stage": "mature",
"price_at_rating": 115.17,
"signal_short": "BUY_ACCUMULATE", "signal_medium": "BUY", "signal_long": "BUY",
"primary_signal": "BUY",
"quality_score": 67, "valuation_score": 65, "timing_score": 51,
"driver_score": 54, "driver_label": "Neutral",
"driver_name": "Pipeline vs. Keytruda patent cliff",
"economic_alignment_stance": "Trend-Following", "economic_alignment_conviction": 62,
"economic_alignment_pressure": "Tailwind", "economic_alignment_source": "sector-map",
"macro_report_date": "2026-06-13",
"amplification_fired": false,
"quality_detail": { "industry_benchmark_name": "R&D Efficiency + Patent Cliff",
"industry_benchmark_value": "Keytruda ~49% of revenue", "industry_benchmark_score": 52,
"moat_score": 64, "roic_capital_score": 70, "keytruda_pct_total_revenue": 49 },
"valuation_detail": { "fwd_pe_normalized": 12.8, "trailing_pe_reported": 31.9,
"pe_on_2026_guide": 22.4, "fcf_yield_normalized": 6.0, "fcf_yield_reported_ttm": 4.3,
"normalized_eps": 9.0, "implied_growth_rate": 2.5, "consensus_growth_rate": 6.0,
"historical_valuation_decile": 3, "cidara_iprd_charge_usd_b": 9 },
"timing_detail": { "mtf_confluence": 57, "risk_reward_score": 48,
"relative_strength": "strong (+50% off 52wk low)", "catalyst_clustering_score": 70,
"dynamic_macro_weight": 0.10 },
"analyst_consensus_target": 131.58, "analyst_target_high": 150, "analyst_target_low": 100,
"analyst_target_median": 135, "analyst_target_upside_pct": 14.3,
"analyst_grades_consensus": "Buy", "analyst_bullish_pct": 67.6, "analyst_coverage_count": 37,
"recent_upgrades_30d": 0, "recent_downgrades_30d": 0,
"fmp_rating": "B", "fmp_overall_score": 3,
"overall_confidence": 66,
"fair_value_est": 131, "stop_loss": 104.50, "target_price": 131,
"scenario_bull": 148, "scenario_base": 131, "scenario_bear": 98,
"hard_gate_state": "caution",
"gates_triggered": [], "gates_caution": ["accounting_gaap_nongaap_gap", "drug_pricing_ira", "keytruda_concentration_patent_cliff"],
"do_not_buy_triggers": [],
"entry_criteria_total": 3, "entry_criteria_met": 1,
"exit_criteria_total": 3, "exit_criteria_met": 0,
"next_update_date": "2026-06-30", "next_check_date": "2026-06-30",
"next_update_basis": "default +14d (next earnings ~2026-07-28 beyond 14d window)"
}
15
Data Sources & Methodology
Audit trail of every data source: ✓ available, ⚠ partial/fallback, ✗ failed, plus the confidence haircuts applied. Consult this if a number looks off or to see why confidence sits below the raw composite.
Data Source Status
✓
get_company_profile / get_stock_snapshot — price $115.17, mkt cap $284.4B, 2.47B shares verified
✓
get_income_statement (6q) — Q1'26 IPR&D charge identified & normalized
✓
get_financial_ratios — margins, leverage, coverage, FCF
✓
get_multi_timeframe_analysis — all 5 timeframes incl. intraday
✓
get_stock_prices (6mo) — 125 daily bars for chart
✓
price_target_consensus / summary — $131.58 cons / $100-150 range
✓
grades_consensus / stock_grades — 25/11/1; all "maintain"
✓
ratings_snapshot — FMP B (3/5)
⚠
get_analyst_estimates — annual to 2030; thin analyst counts on out-years
✓
economic_calendar / key_economic_indicators — FOMC Jun 17, regime read
✗
get_earnings_calendar — no dated row; Q2 date ~Jul 28 estimated
⚠
get_stock_news + web — light direct flow; Cidara charge & 2026 guide confirmed via SEC/web
Impact on scores: Valuation confidence trimmed ~10% for the wide analyst-target spread and the manual EPS-normalization step (vs. clean reported numbers). Timing built on full intraday + 6-month price data — no haircut there, but the missing dated earnings means the ~Jul 28 catalyst date is provisional (scheduling is robust regardless, as it falls beyond the 14-day window). Driver confidence 62% reflects the contested timing/magnitude of the 2028 cliff. Data-basis trap actively handled: reported P/E (31.9x trailing, 22.4x on the 2026 guide) and TTM FCF yield are distorted by the ~$9B one-time Cidara IPR&D charge and were normalized before scoring.
DISCLAIMER: This is a quantitative framework for educational purposes only. It is not financial advice. Always do your own research and consult a licensed financial advisor before making investment decisions.